Breast Cancer PSMA PET

Part of paid clinical trials in Iowa City, Iowa.

Sponsor
Ahmad Shariftabrizi
Study ID
NCT06586047
Phase
EARLY_PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

  • PET imaging — DIAGNOSTIC_TEST
    Imaging with FDG PET/CT and Pyl PET/CT in triple negative breast cancer

Study Details

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

Key Dates

Start date
Aug 29, 2024
Status verified
Mar 2026
Primary completion
Dec 29, 2026
Completion
Dec 29, 2026

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: PET Imaging of breast cancer patients
    Triple negative breast cancer patients will undergo FDG PET/CT and Pyl PET/Ct

Primary Outcome Measure

Lesion detection sensitivity analysis [ Time Frame: 4 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Iowa HealthcareIowa CityIowa52242
Ahmad Shariftabrizi, M.D.
[email protected]
319-887-4942

Find similar trials in Iowa City, IA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
University of Iowa Healthcare· Iowa City, IA

Related Studies